author-photo

F. Jin

Merck & Co.

3

Papers

416

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (306)
LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (105)
11TiPPhase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (5)